Literature DB >> 22932779

In reply: response to Marioni.

David N Church, Denis C Talbot.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 22932779     DOI： 10.1007/s11912-012-0268-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  3 in total

1.  Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.

Authors:  Denis C Talbot; Malcolm Ranson; Joanna Davies; Michael Lahn; Sophie Callies; Valérie André; Sunil Kadam; Michael Burgess; Christopher Slapak; Anna L Olsen; Peter J McHugh; Johann S de Bono; Julian Matthews; Azeem Saleem; Patricia Price
Journal:  Clin Cancer Res       Date:  2010-11-01       Impact factor: 12.531

2.  Rationale behind survivin inhibition as a potential therapeutic strategy in head and neck carcinoma too.

Authors:  Gino Marioni
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

3.  Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Authors:  Anthony W Tolcher; Alain Mita; Lionel D Lewis; Christopher R Garrett; Elizabeth Till; Adil I Daud; Amita Patnaik; Kyri Papadopoulos; Chris Takimoto; Pamela Bartels; Anne Keating; Scott Antonia
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 50.717
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.